Clinical trials: First Relapse
Relapsed Malignant Solid Neoplasm
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
- Trial name
- NCT05865002
- Testing
- AUR107
- Where
- 37 sites in India
- Volunteers
- 50 people
- Sponsor
- Aurigene Discovery Technologies Limited
Hodgkin Lymphoma
Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
This is a retrospective, monocenter and non-interventional study. Data were retrospectively collected from all patients who completed the BV-Bs scheme in the time period between 1 September 2013 and 1 September 2023.
- Trial name
- HL_PR/R-B (NCT06295211)
- Testing
- observational
- Volunteers
- 32 people
- Sponsor
- Federico II University
Leukemia, Myeloid, Acute
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.
This study is a randomized, multicenter, open-label, Phase 2 study that will be run in 2 parts: a safety run-in part to determine the dose of azacitidine and then a second part to determine the efficacy of that dose in children…
- Trial name
- NCT02450877
- Testing
- Azacitidine, Control Arm
- Where
- 8 sites in Denmark, Germany and 1 more
- Volunteers
- 7 people
- Sponsor
- Celgene
Brain and Central Nervous System Tumors
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of leflunomide in treating patients who have anaplastic…
- Trial name
- NCT00003775
- Testing
- leflunomide
- Where
- 26 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Pfizer
B-cell Acute Lymphoblastic Leukemia
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL.
- Trial name
- ELIANA (NCT02435849)
- Testing
- CTL019
- Where
- 23 sites in United States, Australia and 9 more
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Chronic Lymphocytic Leukemia
AMG 319 Lymphoid Malignancy FIH
This is a multi-center, phase 1, open-label first-in-human study of AMG 319 in subjects with relapsed or refractory lymphoid malignancies. This study consists of two parts.
- Conditions
- Cancer, Chronic Lymphocytic Leukemia, Diffuse Large Cell Lymphoma, Hematologic Malignancies
- Trial name
- NCT01300026
- Testing
- AMG 319
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Amgen
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed).
- Trial name
- NCT04546399
- Testing
- 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection
- Where
- 227 sites in United States, Australia and 2 more
- Volunteers
- 461 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
RATIONALE: Providing information that is tailored to answer patients' questions about clinical trials may help patients with cancer decide to enroll in a clinical trial.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00750009
- Testing
- educational intervention
- Where
- 4 sites in United States
- Volunteers
- 583 people
- Sponsor
- Case Comprehensive Cancer Center
Relapse, Advanced Malignant Neoplasm
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients with Select Relapsed Advanced Malignancies (JIVAN).
- Conditions
- Relapse, Advanced Malignant Neoplasm, Non Small Cell Lung Cancer, Gastric Cancer
- Trial name
- JIVAN (NCT05861947)
- Testing
- AUR106
- Where
- 6 sites in India
- Volunteers
- 21 people
- Sponsor
- Aurigene Discovery Technologies Limited
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma.
- Conditions
- Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
- Trial name
- NCT05512390
- Testing
- ABBV-319
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 39 people
- Sponsor
- AbbVie
Relapsed/Refractory Large B-Cell Lymphoma
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
To evaluate the efficacy and safety of Linperlisib combined with standard immunochemotherapy in patients with R/R LBCL.
- Trial name
- NCT06489808
- Testing
- Linperlisib, Rituximab, Gemcitabine
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Relapsed/Refractory Multiple Myeloma
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined).
- Trial name
- COSTIMM (NCT06669247)
- Testing
- Linvoseltamab, REGN7945+Linvoseltamab
- Where
- 9 sites in Australia, United Kingdom
- Volunteers
- 186 people
- Sponsor
- Regeneron Pharmaceuticals
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Surgery for Relapsed Ovarian Cancer in Precision
This multicenter, biomarker-driven, patient-centric study aimed to evaluate the efficacy of secondary cytoreduction followed by platinum-based chemotherapy in combination with anti-PD1/CTLA-4 bispecifics therapy in patients with…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT06602063
- Testing
- surgery/chemotherapy, Iparomlimab/Tuvonralimab
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Advanced Malignant Neoplasm, Acute Myeloid Leukemia
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies.
- Conditions
- Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia
- Trial name
- NCT04067336
- Testing
- Ziftomenib, Midazolam, Itraconazole
- Where
- 43 sites in United States, Belgium and 5 more
- Volunteers
- 263 people
- Sponsor
- Kura Oncology, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with…
- Trial name
- NCT06419634
- Testing
- BMS-986497, Azacitidine, Venetoclax
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 34 people
- Sponsor
- Bristol-Myers Squibb
Effect of Drug, Drug
Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
Apatinib has led to positive responses in the treatment of osteosarcoma refractory to first-line chemotherapy. However, apatinib demonstrates only short-lived activity, and the disease control of musculoskeletal lesions is worse…
- Conditions
- Effect of Drug, Drug, Toxicity
- Trial name
- OAIE (NCT05277480)
- Testing
- Apatinib+IE, IE
- Where
- 5 sites in China
- Volunteers
- 81 people
- Sponsor
- Peking University People's Hospital
Relapsed/Refractory Acute Myeloid Leukemia
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
The purpose of this study is to determine if a combination of nintedanib+ induction chemotherapy can be an effective strategy for patients where outcome of relapse/refractory acute myeloid leukemia (AML) is poor.
- Trial name
- NCT02665143
- Testing
- Nintedanib and AML induction
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Yale University
Ovarian Neoplasms
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)
This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive…
- Trial name
- NCT01329549
- Testing
- BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- Where
- 3 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy.
- Trial name
- NCT01137968
- Testing
- imetelstat, Bevacizumab
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 116 people
- Sponsor
- Geron Corporation
Solid Tumor, Adult
Phase 1a Study to Evaluate Immunogenicity of ASV®
This is an open-label Phase 1a First-in-Human Study to determine Safety and Tolerability of ASV® AGEN2017 with QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Tumors at Risk of Relapse Undergoing Observation as…
- Trial name
- NCT03673020
- Testing
- ASV® AGEN2017 + QS-21 Stimulon® adjuvant
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Agenus Inc.